# Single Ascending and Multiple Dose Study to Evaluate Safety, Tolerability, and PK of MYMD1 in Healthy Male and Female Adult Subjects

> **NCT05077865** · PHASE1 · COMPLETED · sponsor: **TNF Pharmaceuticals, Inc.** · enrollment: 32 (actual)

## Conditions studied

- Hashimoto Disease

## Interventions

- **DRUG:** MYMD-1
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05077865
- **Lead sponsor:** TNF Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-04-26
- **Primary completion:** 2021-08-01
- **Final completion:** 2021-08-01
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2023-03-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05077865

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05077865, "Single Ascending and Multiple Dose Study to Evaluate Safety, Tolerability, and PK of MYMD1 in Healthy Male and Female Adult Subjects". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05077865. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*